BRAF controls the effects of metformin on neuroblast cell divisions in C. elegans
Abstract
Metformin has demonstrated substantial potential for use in cancer treatments. LKB-AMPK and mTOR are reported to be the main targets of metformin in relation to its ability to prevent cancer cell proliferation. However, the role of metformin in the control of neoplastic cancer cell growth is possibly independent of LKB-AMPK and mTOR. Using C. elegans as a model, we found that the neuronal Q-cell divisions in L1-arrested worms were suppressed following metformin treatment in AMPK-deficient mutants, suggesting that the mechanism by which metformin suppresses these cell divisions is independent of AMPK. Our results showed that the mTOR pathway indeed played a role in controlling germ cell proliferation, but it was not involved in the neuronal Q-cell divisions occurring in L1-arrested worms. We found that the neuronal Q-cells divisions were hold at G1/S cell stage by metformin in vivo. Additionally, we demonstrated that metformin could reduce the phosphorylation activity of BRAF and block the BRAF-MAPK oncogenesis pathway to regulate neuronal Q-cell divisions during L1 arrest. This work discloses a new mechanism by which metformin treatment acts to promote neuronal cancer prevention, and these results will help promote the study of the anticancer mechanisms underlying metformin treatments.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 6
- FWCI
- 0.49
- Field percentile
- top 42%
- Organism
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Translational control of AMPK activity in melanoma
Natália Vadovičová, Anna Lešková, … Stjepan Uldrijan·Cell Communication and SignalingPeer-reviewed·Apr 28, 2026
- Identification of glucose-independent metabolic pathways associated with anti-proliferative effect of metformin, their coordinate derangement with cMyc downregulation and reversibility in liver cancer cells.
S. R. Islam, S. K. Manna·bioRxiv·Aug 4, 2023
- Medroxyprogesterone reverses tolerable dose metformin-induced inhibition of invasion via matrix metallopeptidase-9 and transforming growth factor-β1 in KLE endometrial cancer cells
D. H. Suh, S. Lee, … N. H. Park·bioRxiv·Apr 2, 2019
- AMPK activation by metformin promotes survival of dormant ER+ breast cancer cells
R. A. Hampsch, J. D. Wells, … T. W. Miller·bioRxiv·Jan 21, 2020
- Comparison of the effects of metformin on MDA-MB-231 breast cancer cells in a monolayer culture and in tumour spheroids as a function of nutrient concentrations
M. Bizjak, P. Malavasic, … M. Pavlin·bioRxiv·Jun 20, 2018
- The Mixed Blessing of AMPK Signaling in Cancer Treatments
Mehrshad Sadria, Deokhwa Seo, Anita T. Layton·BMC CancerPeer-reviewed·Jan 25, 2022